secwatch.observer — SEC 8-K summary
======================================

Issuer:     Pyxis Oncology, Inc. (PYXS)
CIK:        0001782223
Form:       8-K
Filed at:   2025-12-18T23:59:59+00:00
Accession:  0001193125-25-323704
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pyxis Oncology MICVO Phase 1 shows 46% ORR monotherapy, 71% ORR with Keytruda in HNSCC
--------------------------------------------------------------------------------

- MICVO monotherapy at 5.4 mg/kg: 46% confirmed ORR (6/13), 92% DCR in 2L+ R/M HNSCC; no Grade 4/5 TRAEs.
- MICVO + Keytruda (3.6/4.4 mg/kg): 71% confirmed ORR (5/7), 100% DCR in 1L/2L+ HNSCC; no TRAE discontinuations.
- Sold Enzeshu royalty rights for $11M one-time cash; cash runway extends into Q4 2026.
- Monotherapy update expected mid-2026; combo update in 2H26; FDA alignment on pivotal study design obtained.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1782223/000119312525323704/0001193125-25-323704-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1782223/000119312525323704/pyxs-20251218.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-323704

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer